Exicure Corp - רווח נקי למניה אחת בשנים עשר החודשים האחרונים XCUR

Exicure, Inc. is implementing innovative SNA technologies for the precision therapy of neurological and skin pathologies. The annual percentage change in earnings per share (TTM) helps assess the effectiveness of this approach, where the value 22.90 describes the current yield level. The issuer's prospects depend on the sale of platform licenses amidst patent disputes, while its US localization minimizes geopolitical risks.
Exicure - פילוחים אנליטיים ומדדי מפתח (XCUR)

Amidst the fierce battle for RNA therapy patents, Exicure, Inc. is exposed to high risks of scientific failure during early-stage development. By analyzing this EPS YoY TTM chart with a value of 22.90, we assess the annual EPS (TTM) growth rate, which allows us to identify systemic degradation or business resilience to determine the asset's margin of safety.